Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Rheumatoid Arthritis

  Free Subscription


Articles published in Ann Rheum Dis

Retrieve available abstracts of 163 articles:
HTML format
Text format



Single Articles


    May 2017
  1. MEISSNER Y, Richter A, Manger B, Tony HP, et al
    Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort.
    Ann Rheum Dis. 2017 May 8. pii: annrheumdis-2017-211209.
    PubMed     Text format     Abstract available


  2. SMOLEN JS, Landewe RBM, van der Heijde D
    Response to: '2016 update of the EULAR recommendations for the management of rheumatoid arthritis: no utopia for patients in low/middle-income countries?' by Misra et al.
    Ann Rheum Dis. 2017 May 6. pii: annrheumdis-2017-211455.
    PubMed     Text format    


  3. BUTTGEREIT F, Bijlsma JW
    Glucocorticoids in rheumatoid arthritis: the picture is shaping up.
    Ann Rheum Dis. 2017 May 4. pii: annrheumdis-2017-211187.
    PubMed     Text format    


  4. PARK JK, Lee MA, Lee EY, Song YW, et al
    Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial.
    Ann Rheum Dis. 2017 May 3. pii: annrheumdis-2017-211128.
    PubMed     Text format     Abstract available


    April 2017
  5. SAFY M, Jacobs J, IJff ND, Bijlsma J, et al
    Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial.
    Ann Rheum Dis. 2017 Apr 27. pii: annrheumdis-2016-210647.
    PubMed     Text format     Abstract available


  6. PIRILA L, Sokka T, Kauppi MJ, Rantalaiho VM, et al
    Alternative interpretation of data for recommendations on how to manage rheumatoid arthritis.
    Ann Rheum Dis. 2017 Apr 27. pii: annrheumdis-2017-211505.
    PubMed     Text format    


  7. CRUZ GI, Shao X, Quach H, Ho KA, et al
    Increased risk of rheumatoid arthritis among mothers with children who carry DRB1 risk-associated alleles.
    Ann Rheum Dis. 2017 Apr 8. doi: 10.1136/annrheumdis-2016-210662.
    PubMed     Text format     Abstract available


  8. BURMESTER GR, Rigby WF, van Vollenhoven RF, Kay J, et al
    Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.
    Ann Rheum Dis. 2017 Apr 7. pii: annrheumdis-2016-210561.
    PubMed     Text format     Abstract available


    March 2017
  9. CHATZIDIONYSIOU K, Emamikia S, Nam J, Ramiro S, et al
    Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Ann Rheum Dis. 2017 Mar 29. pii: annrheumdis-2016-210711.
    PubMed     Text format     Abstract available


  10. MISRA DP, Agarwal V, Sharma A, Wakhlu A, et al
    2016 update of the EULAR recommendations for the management of rheumatoid arthritis: a utopia beyond patients in low/middle income countries?
    Ann Rheum Dis. 2017 Mar 27. pii: annrheumdis-2017-211446.
    PubMed     Text format    


  11. HUMPHREYS JH, Warner A, Costello R, Lunt M, et al
    Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate.
    Ann Rheum Dis. 2017 Mar 23. pii: annrheumdis-2016-210629.
    PubMed     Text format     Abstract available


  12. MANIVEL VA, Mullazehi M, Padyukov L, Westerlind H, et al
    Anticollagen type II antibodies are associated with an acute onset rheumatoid arthritis phenotype and prognosticate lower degree of inflammation during 5 years follow-up.
    Ann Rheum Dis. 2017 Mar 23. pii: annrheumdis-2016-210873.
    PubMed     Text format     Abstract available


  13. RAMIRO S, Sepriano A, Chatzidionysiou K, Nam JL, et al
    Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.
    Ann Rheum Dis. 2017 Mar 15. pii: annrheumdis-2016-210708.
    PubMed     Text format     Abstract available


  14. BAKER JF, Ostergaard M, Conaghan PG
    Is MRI a predictive biomarker for clinical response to biologics in rheumatoid arthritis?
    Ann Rheum Dis. 2017 Mar 10. pii: annrheumdis-2017-211265.
    PubMed     Text format    


  15. SEWERIN P, Vordenbaeumen S, Brinks R, Ostendorf B, et al
    Prospective MRI score to predict negative EULAR response in patients with rheumatoid arthritis (RA) before therapy-escalation to a biological therapy.
    Ann Rheum Dis. 2017 Mar 10. pii: annrheumdis-2017-211257.
    PubMed     Text format    


  16. NAM JL, Takase-Minegishi K, Ramiro S, Chatzidionysiou K, et al
    Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Ann Rheum Dis. 2017 Mar 10. pii: annrheumdis-2016-210713.
    PubMed     Text format     Abstract available


  17. ARENDS S, Trouw LA, Toes RE, van Zanten A, et al
    Identification of Lifelines participants at high risk for development of rheumatoid arthritis.
    Ann Rheum Dis. 2017 Mar 8. pii: annrheumdis-2017-211256.
    PubMed     Text format    


  18. MAHLER M
    Population-based screening for ACPAs: a step in the pathway to the prevention of rheumatoid arthritis?
    Ann Rheum Dis. 2017 Mar 8. pii: annrheumdis-2017-211249.
    PubMed     Text format    


  19. SMOLEN JS, Landewe R, Bijlsma J, Burmester G, et al
    EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
    Ann Rheum Dis. 2017 Mar 6. pii: annrheumdis-2016-210715.
    PubMed     Text format     Abstract available


    February 2017
  20. MANKIA K, Emery P
    Imminent rheumatoid arthritis can be identified in primary care.
    Ann Rheum Dis. 2017 Feb 28. pii: annrheumdis-2017-211231.
    PubMed     Text format    


  21. BURMESTER GR, McInnes IB, Kremer J, Miranda P, et al
    A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.
    Ann Rheum Dis. 2017 Feb 17. pii: annrheumdis-2016-210624.
    PubMed     Text format     Abstract available


  22. ROUBILLE C, Rincheval N, Dougados M, Flipo RM, et al
    Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort.
    Ann Rheum Dis. 2017 Feb 17. pii: annrheumdis-2016-210135.
    PubMed     Text format     Abstract available


  23. OSPELT C, Bang H, Feist E, Camici G, et al
    Carbamylation of vimentin is inducible by smoking and represents an independent autoantigen in rheumatoid arthritis.
    Ann Rheum Dis. 2017 Feb 9. pii: annrheumdis-2016-210059.
    PubMed     Text format     Abstract available


  24. ATSUMI T, Tanaka Y, Yamamoto K, Takeuchi T, et al
    Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.
    Ann Rheum Dis. 2017 Feb 2. pii: annrheumdis-2016-210246.
    PubMed     Text format     Abstract available


    January 2017
  25. COHEN SB, Tanaka Y, Mariette X, Curtis JR, et al
    Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
    Ann Rheum Dis. 2017 Jan 31. pii: annrheumdis-2016-210457.
    PubMed     Text format     Abstract available


  26. HU Y, Sparks JA, Malspeis S, Costenbader KH, et al
    Long-term dietary quality and risk of developing rheumatoid arthritis in women.
    Ann Rheum Dis. 2017 Jan 30. pii: annrheumdis-2016-210431.
    PubMed     Text format     Abstract available


  27. ALIVERNINI S, Tolusso B, Petricca L, Bui L, et al
    Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
    Ann Rheum Dis. 2017 Jan 24. pii: annrheumdis-2016-210424.
    PubMed     Text format     Abstract available


  28. SMOLEN JS, Agarwal SK, Ilivanova E, Xu XL, et al
    A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate.
    Ann Rheum Dis. 2017 Jan 13. pii: annrheumdis-2016-209831.
    PubMed     Text format     Abstract available


  29. OLOFSSON T, Petersson IF, Eriksson JK, Englund M, et al
    Predictors of work disability after start of anti-TNF therapy in a national cohort of Swedish patients with rheumatoid arthritis: does early anti-TNF therapy bring patients back to work?
    Ann Rheum Dis. 2017 Jan 10. pii: annrheumdis-2016-210239.
    PubMed     Text format     Abstract available


  30. LOW AS, Symmons DP, Lunt M, Mercer LK, et al
    Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2017 Jan 10. pii: annrheumdis-2016-209784.
    PubMed     Text format     Abstract available


  31. D'AGOSTINO MA, Boers M, Wakefield RJ, Emery P, et al
    Is it time to revisit the role of ultrasound in rheumatoid arthritis management?
    Ann Rheum Dis. 2017;76:7-8.
    PubMed     Text format     Abstract available


    December 2016
  32. LACAILLE D, Avina-Zubieta JA, Sayre EC, Abrahamowicz M, et al
    Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap.
    Ann Rheum Dis. 2016 Dec 28. pii: annrheumdis-2016-209562.
    PubMed     Text format     Abstract available


  33. AJEGANOVA S, van der Helm-van Mil A
    Disease-modifying treatment in rheumatoid arthritis: treat early and do not forget to try to taper and stop.
    Ann Rheum Dis. 2016 Dec 23. pii: annrheumdis-2016-210892.
    PubMed     Text format    


  34. ZEIDLER H
    Drug-free sustained remission or spontaneous remission by natural history in rheumatoid arthritis? An unsolved question: comment on the article of Ajeganova et al.
    Ann Rheum Dis. 2016 Dec 22. pii: annrheumdis-2016-210887.
    PubMed     Text format    


  35. BURMESTER GR, Choy E, Kivitz A, Ogata A, et al
    Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2016 Dec 22. pii: annrheumdis-2016-210297.
    PubMed     Text format     Abstract available


  36. WESTHOVENS R, Taylor PC, Alten R, Pavlova D, et al
    Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1
    Ann Rheum Dis. 2016 Dec 19. pii: annrheumdis-2016-210104.
    PubMed     Text format     Abstract available


  37. KAVANAUGH A, Kremer J, Ponce L, Cseuz R, et al
    Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
    Ann Rheum Dis. 2016 Dec 19. pii: annrheumdis-2016-210105.
    PubMed     Text format     Abstract available


  38. VAN DER HELM-VAN MIL A, Landewe R
    Appropriate use of the EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis.
    Ann Rheum Dis. 2016 Dec 15. pii: annrheumdis-2016-210859.
    PubMed     Text format    


  39. PETERFY C, Strand V, Tian L, Ostergaard M, et al
    Short-term changes on MRI predict long-term changes on radiography in rheumatoid arthritis: an analysis by an OMERACT Task Force of pooled data from four randomised controlled trials.
    Ann Rheum Dis. 2016 Dec 14. pii: annrheumdis-2016-210311.
    PubMed     Text format     Abstract available


  40. MANKIA K, Nam J, Emery P
    Identifying arthralgia suspicious for progression to rheumatoid arthritis.
    Ann Rheum Dis. 2016 Dec 8. pii: annrheumdis-2016-210853.
    PubMed     Text format    


    November 2016
  41. VAN TUYL LH, Sadlonova M, Hewlett S, Davis B, et al
    The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission.
    Ann Rheum Dis. 2016 Nov 30. pii: annrheumdis-2016-209835.
    PubMed     Text format     Abstract available


  42. FENT GJ, Greenwood JP, Plein S, Buch MH, et al
    The role of non-invasive cardiovascular imaging in the assessment of cardiovascular risk in rheumatoid arthritis: where we are and where we need to be.
    Ann Rheum Dis. 2016 Nov 28. pii: annrheumdis-2016-209744.
    PubMed     Text format     Abstract available


  43. BURMESTER GR, Lin Y, Patel R, van Adelsberg J, et al
    Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.
    Ann Rheum Dis. 2016 Nov 17. pii: annrheumdis-2016-210310.
    PubMed     Text format     Abstract available


  44. OZEN G, Pedro S, Holmqvist ME, Avery M, et al
    Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis.
    Ann Rheum Dis. 2016 Nov 11. pii: annrheumdis-2016-209954.
    PubMed     Text format     Abstract available


    October 2016
  45. SMOLEN JS, Kremer JM, Gaich CL, DeLozier AM, et al
    Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).
    Ann Rheum Dis. 2016 Oct 31. pii: annrheumdis-2016-209821.
    PubMed     Text format     Abstract available


  46. VAN STEENBERGEN HW, Aletaha D, Beaart-van de Voorde LJ, Brouwer E, et al
    EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis.
    Ann Rheum Dis. 2016 Oct 6. pii: annrheumdis-2016-209846.
    PubMed     Text format     Abstract available


  47. MICHELSEN B, Kristianslund EK, Hammer HB, Fagerli KM, et al
    Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD
    Ann Rheum Dis. 2016 Oct 4. pii: annrheumdis-2016-210283.
    PubMed     Text format     Abstract available


  48. AGCA R, Heslinga SC, Rollefstad S, Heslinga M, et al
    EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.
    Ann Rheum Dis. 2016 Oct 3. pii: annrheumdis-2016-209775.
    PubMed     Text format     Abstract available


  49. HUNT L, Hensor EM, Nam J, Burska AN, et al
    T cell subsets: an immunological biomarker to predict progression to clinical arthritis in ACPA-positive individuals.
    Ann Rheum Dis. 2016;75:1884-9.
    PubMed     Text format     Abstract available


  50. VAN HEEMST J, Hensvold AH, Jiang X, van Steenbergen H, et al
    Protective effect of HLA-DRB1*13 alleles during specific phases in the development of ACPA-positive RA.
    Ann Rheum Dis. 2016;75:1891-8.
    PubMed     Text format     Abstract available


  51. CORSIERO E, Bombardieri M, Carlotti E, Pratesi F, et al
    Single cell cloning and recombinant monoclonal antibodies generation from RA synovial B cells reveal frequent targeting of citrullinated histones of NETs.
    Ann Rheum Dis. 2016;75:1866-75.
    PubMed     Text format     Abstract available


  52. VAN STEENBERGEN HW, Mangnus L, Reijnierse M, Huizinga TW, et al
    Clinical factors, anticitrullinated peptide antibodies and MRI-detected subclinical inflammation in relation to progression from clinically suspect arthralgia to arthritis.
    Ann Rheum Dis. 2016;75:1824-30.
    PubMed     Text format     Abstract available


    September 2016
  53. GIOLLO A, Cioffi G, Ognibeni F, Dalbeni A, et al
    Disease activity and left ventricular systolic function in rheumatoid arthritis.
    Ann Rheum Dis. 2016 Sep 28. pii: annrheumdis-2016-210482.
    PubMed     Text format    


  54. VAN DER HELM-VAN MIL AH, Zink A
    What is rheumatoid arthritis? Considering consequences of changed classification criteria.
    Ann Rheum Dis. 2016 Sep 22. pii: annrheumdis-2016-209629.
    PubMed     Text format    


  55. YOO DH, Suh CH, Shim SC, Jeka S, et al
    A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2016 Sep 13. pii: annrheumdis-2016-209540.
    PubMed     Text format     Abstract available


  56. AMMITZBOLL-DANIELSEN M, Ostergaard M, Fana V, Glinatsi D, et al
    Intramuscular versus ultrasound-guided intratenosynovial glucocorticoid injection for tenosynovitis in patients with rheumatoid arthritis: a randomised, double-blind, controlled study.
    Ann Rheum Dis. 2016 Sep 7. pii: annrheumdis-2016-209840.
    PubMed     Text format     Abstract available


    August 2016
  57. NIEUWENHUIS WP, de Wit MP, Boonen A, van der Helm-van Mil AH, et al
    Changes in the clinical presentation of patients with rheumatoid arthritis from the early 1990s to the years 2010: earlier identification but more severe patient reported outcomes.
    Ann Rheum Dis. 2016 Aug 24. pii: annrheumdis-2016-209949.
    PubMed     Text format    


  58. D'AGOSTINO MA, Terslev L, Wakefield R, Ostergaard M, et al
    Novel algorithms for the pragmatic use of ultrasound in the management of patients with rheumatoid arthritis: from diagnosis to remission.
    Ann Rheum Dis. 2016 Aug 23. pii: annrheumdis-2016-209646.
    PubMed     Text format     Abstract available


  59. MERCER LK, Galloway JB, Lunt M, Davies R, et al
    Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Ann Rheum Dis. 2016 Aug 8. pii: annrheumdis-2016-209389.
    PubMed     Text format     Abstract available


  60. DEKKERS JS, Schoones JW, Huizinga TW, Toes RE, et al
    Possibilities for preventive treatment in rheumatoid arthritis? Lessons from experimental animal models of arthritis: a systematic literature review and meta-analysis.
    Ann Rheum Dis. 2016 Aug 1. pii: annrheumdis-2016-209830.
    PubMed     Text format     Abstract available


    July 2016
  61. ANGIOLILLI C, Kabala PA, Grabiec AM, Van Baarsen IM, et al
    Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes.
    Ann Rheum Dis. 2016 Jul 25. pii: annrheumdis-2015-209064.
    PubMed     Text format     Abstract available


  62. VERSCHUEREN P, De Cock D, Corluy L, Joos R, et al
    Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic ope
    Ann Rheum Dis. 2016 Jul 18. pii: annrheumdis-2016-209212.
    PubMed     Text format     Abstract available


  63. BAKER JF, Conaghan PG, Emery P, Baker DG, et al
    Relationship of patient-reported outcomes with MRI measures in rheumatoid arthritis.
    Ann Rheum Dis. 2016 Jul 18. pii: annrheumdis-2016-209463.
    PubMed     Text format     Abstract available


  64. STRANGFELD A, Richter A, Siegmund B, Herzer P, et al
    Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.
    Ann Rheum Dis. 2016 Jul 12. pii: annrheumdis-2016-209773.
    PubMed     Text format     Abstract available



  65. Correction: Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.
    Ann Rheum Dis. 2016;75:e46.
    PubMed     Text format    



  66. Correction: Delays in assessment of patients with rheumatoid arthritis: variations across Europe.
    Ann Rheum Dis. 2016;75:1422.
    PubMed     Text format    


    June 2016
  67. ROSSINI M, Adami G, Viapiana O, Idolazzi L, et al
    Denosumab, cortical bone and bone erosions in rheumatoid arthritis.
    Ann Rheum Dis. 2016 Jun 23. pii: annrheumdis-2016-210022.
    PubMed     Text format    


  68. BURMESTER GR, Landewe R, Genovese MC, Friedman AW, et al
    Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2016 Jun 23. pii: annrheumdis-2016-209322.
    PubMed     Text format     Abstract available


  69. ZHANG Y, Lu N, Peloquin C, Dubreuil M, et al
    Improved survival in rheumatoid arthritis: a general population-based cohort study.
    Ann Rheum Dis. 2016 Jun 23. pii: annrheumdis-2015-209058.
    PubMed     Text format     Abstract available


  70. FIGUEIREDO CP, Bang H, Cobra JF, Englbrecht M, et al
    Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs.
    Ann Rheum Dis. 2016 Jun 20. pii: annrheumdis-2016-209297.
    PubMed     Text format     Abstract available


  71. MERCER LK, Askling J, Raaschou P, Dixon WG, et al
    Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers.
    Ann Rheum Dis. 2016 Jun 15. pii: annrheumdis-2016-209285.
    PubMed     Text format     Abstract available


  72. ERIKSSON JK, Jacobsson L, Bengtsson K, Askling J, et al
    Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis?
    Ann Rheum Dis. 2016 Jun 9. pii: annrheumdis-2016-209315.
    PubMed     Text format     Abstract available


  73. MIDTBO H, Semb AG, Matre K, Kvien TK, et al
    Disease activity is associated with reduced left ventricular systolic myocardial function in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2016 Jun 7. pii: annrheumdis-2016-209223.
    PubMed     Text format     Abstract available


  74. ALVARO-GRACIA JM, Jover JA, Garcia-Vicuna R, Carreno L, et al
    Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial.
    Ann Rheum Dis. 2016 Jun 7. pii: annrheumdis-2015-208918.
    PubMed     Text format     Abstract available


  75. SCHETT G, Emery P, Tanaka Y, Burmester G, et al
    Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.
    Ann Rheum Dis. 2016 Jun 3. pii: annrheumdis-2016-209201.
    PubMed     Text format     Abstract available


    May 2016
  76. JANI M, Isaacs JD, Morgan AW, Wilson AG, et al
    High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort.
    Ann Rheum Dis. 2016 May 31. pii: annrheumdis-2015-208849.
    PubMed     Text format     Abstract available


  77. MARQUEZ A, Vidal-Bralo L, Rodriguez-Rodriguez L, Gonzalez-Gay MA, et al
    A combined large-scale meta-analysis identifies COG6 as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythematosus.
    Ann Rheum Dis. 2016 May 18. pii: annrheumdis-2016-209436.
    PubMed     Text format     Abstract available


  78. GAN RW, Demoruelle MK, Deane KD, Weisman MH, et al
    Omega-3 fatty acids are associated with a lower prevalence of autoantibodies in shared epitope-positive subjects at risk for rheumatoid arthritis.
    Ann Rheum Dis. 2016 May 17. pii: annrheumdis-2016-209154.
    PubMed     Text format     Abstract available


  79. HIFINGER M, Hiligsmann M, Ramiro S, Watson V, et al
    Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists.
    Ann Rheum Dis. 2016 May 17. pii: annrheumdis-2016-209202.
    PubMed     Text format     Abstract available


  80. EMERY P, Bingham CO 3rd, Burmester GR, Bykerk VP, et al
    Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III stud
    Ann Rheum Dis. 2016 May 10. pii: annrheumdis-2015-209057.
    PubMed     Text format     Abstract available


  81. EMERY P, Vencovsky J, Ghil J
    Response to: 'Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required' by Moots et al.
    Ann Rheum Dis. 2016;75:e25.
    PubMed     Text format    


  82. SOLOMON DH, Kim SC
    Potential confounding in colchicine and cardiovascular disease study.
    Ann Rheum Dis. 2016;75:e27.
    PubMed     Text format    


  83. MONTOYA J, Matta NB, Suchon P, Guzian MC, et al
    Patients with ankylosing spondylitis have been breast fed less often than healthy controls: a case-control retrospective study.
    Ann Rheum Dis. 2016;75:879-82.
    PubMed     Text format     Abstract available


  84. MICELI-RICHARD C, Wang-Renault SF, Boudaoud S, Busato F, et al
    Overlap between differentially methylated DNA regions in blood B lymphocytes and genetic at-risk loci in primary Sjogren's syndrome.
    Ann Rheum Dis. 2016;75:933-40.
    PubMed     Text format     Abstract available


  85. STORCH H, Zimmermann B, Resch B, Tykocinski LO, et al
    Activated human B cells induce inflammatory fibroblasts with cartilage-destructive properties and become functionally suppressed in return.
    Ann Rheum Dis. 2016;75:924-32.
    PubMed     Text format     Abstract available


  86. BABOOLAL TG, Mastbergen SC, Jones E, Calder SJ, et al
    Synovial fluid hyaluronan mediates MSC attachment to cartilage, a potential novel mechanism contributing to cartilage repair in osteoarthritis using knee joint distraction.
    Ann Rheum Dis. 2016;75:908-15.
    PubMed     Text format     Abstract available


    April 2016
  87. VERHEUL MK, van Erp SJ, van der Woude D, Levarht EW, et al
    Anti-carbamylated protein antibodies: a specific hallmark for rheumatoid arthritis. Comparison to conditions known for enhanced carbamylation; renal failure, smoking and chronic inflammation.
    Ann Rheum Dis. 2016 Apr 29. pii: annrheumdis-2016-209248.
    PubMed     Text format    


  88. YOO DH, Prodanovic N, Jaworski J, Miranda P, et al
    Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
    Ann Rheum Dis. 2016 Apr 29. pii: annrheumdis-2015-208786.
    PubMed     Text format     Abstract available


  89. NDONGO-THIAM N, Clement A, Pin JJ, Razanajaona-Doll D, et al
    Negative association between autoantibodies against IL-17, IL-17/anti-IL-17 antibody immune complexes and destruction in rheumatoid arthritis.
    Ann Rheum Dis. 2016 Apr 29. pii: annrheumdis-2016-209149.
    PubMed     Text format    


  90. AJEGANOVA S, van Steenbergen HW, Verheul MK, Forslind K, et al
    The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor.
    Ann Rheum Dis. 2016 Apr 26. pii: annrheumdis-2015-208870.
    PubMed     Text format     Abstract available


  91. CURTIS JR, Xie F, Yun H, Bernatsky S, et al
    Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.
    Ann Rheum Dis. 2016 Apr 25. pii: annrheumdis-2016-209131.
    PubMed     Text format     Abstract available


  92. DURAN J, Bockorny M, Dalal D, LaValley M, et al
    Methotrexate dosage as a source of bias in biological trials in rheumatoid arthritis: a systematic review.
    Ann Rheum Dis. 2016 Apr 18. pii: annrheumdis-2016-209383.
    PubMed     Text format     Abstract available


  93. GENOVESE MC, Yang F, Ostergaard M, Kinnman N, et al
    Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings.
    Ann Rheum Dis. 2016 Apr 15. pii: annrheumdis-2015-208901.
    PubMed     Text format     Abstract available


  94. GASPARYAN AY, Kitas GD
    Platelets in rheumatoid arthritis: exploring the anti-inflammatory and antithrombotic potential of TNF inhibitors.
    Ann Rheum Dis. 2016 Apr 4. pii: annrheumdis-2015-208720.
    PubMed     Text format    


  95. STAMM T, Stoffer M, Smolen J
    Response to: 'Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update' by Goswami et al.
    Ann Rheum Dis. 2016 Apr 4. pii: annrheumdis-2016-209499.
    PubMed     Text format    


  96. SMOLEN JS, Collaud Basset S, Boers M, Breedveld F, et al
    Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease.
    Ann Rheum Dis. 2016 Apr 1. pii: annrheumdis-2016-209429.
    PubMed     Text format     Abstract available


  97. DREYER L, Magyari M, Laursen B, Cordtz R, et al
    Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry.
    Ann Rheum Dis. 2016;75:785-6.
    PubMed     Text format    


  98. SOKOLOVE J, Schiff M, Fleischmann R, Weinblatt ME, et al
    Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial.
    Ann Rheum Dis. 2016;75:709-14.
    PubMed     Text format     Abstract available


  99. NOCTURNE G, Tarn J, Boudaoud S, Locke J, et al
    Germline variation of TNFAIP3 in primary Sjogren's syndrome-associated lymphoma.
    Ann Rheum Dis. 2016;75:780-3.
    PubMed     Text format     Abstract available


  100. PUTRIK P, Ramiro S, Hifinger M, Keszei AP, et al
    In wealthier countries, patients perceive worse impact of the disease although they have lower objectively assessed disease activity: results from the cross-sectional COMORA study.
    Ann Rheum Dis. 2016;75:715-20.
    PubMed     Text format     Abstract available


  101. HERBERT MK, Stammen-Vogelzangs J, Verbeek MM, Rietveld A, et al
    Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases.
    Ann Rheum Dis. 2016;75:696-701.
    PubMed     Text format     Abstract available


  102. FESSLER J, Raicht A, Husic R, Ficjan A, et al
    Premature senescence of T-cell subsets in axial spondyloarthritis.
    Ann Rheum Dis. 2016;75:748-54.
    PubMed     Text format     Abstract available


  103. GALO JS, Mehat P, Rai SK, Avina-Zubieta A, et al
    What are the effects of medication adherence interventions in rheumatic diseases: a systematic review.
    Ann Rheum Dis. 2016;75:667-73.
    PubMed     Text format     Abstract available


  104. HUMPHREYS JH, Symmons DP, Verstappen SM
    Response to: 'Evaluation of the association between anticarbamylated protein antibodies and longitudinal course of functional ability in rheumatoid arthritis' by Ajeganova et al.
    Ann Rheum Dis. 2016;75:e15.
    PubMed     Text format    


  105. SOKOLOVE J, Pisetsky D
    Bone loss, pain and inflammation: three faces of ACPA in RA pathogenesis.
    Ann Rheum Dis. 2016;75:637-9.
    PubMed     Text format    


  106. DERKSEN VF, Ajeganova S, Trouw LA, van der Helm-van Mil AH, et al
    Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present.
    Ann Rheum Dis. 2016;76:716-720.
    PubMed     Text format     Abstract available


    March 2016
  107. GOSWAMI RP, Basu K, Das S, Mondal S, et al
    Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update.
    Ann Rheum Dis. 2016 Mar 29. pii: annrheumdis-2015-209094.
    PubMed     Text format    


  108. DALE J, Stirling A, Zhang R, Purves D, et al
    Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial.
    Ann Rheum Dis. 2016 Mar 29. pii: annrheumdis-2015-208941.
    PubMed     Text format     Abstract available


  109. CLAVEL C, Ceccato L, Anquetil F, Serre G, et al
    Among human macrophages polarised to different phenotypes, the M-CSF-oriented cells present the highest pro-inflammatory response to the rheumatoid arthritis-specific immune complexes containing ACPA.
    Ann Rheum Dis. 2016 Mar 23. pii: annrheumdis-2015-208887.
    PubMed     Text format     Abstract available


  110. LJUNG L, Rantapaa-Dahlqvist S, Jacobsson LT, Askling J, et al
    Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis.
    Ann Rheum Dis. 2016 Mar 16. pii: annrheumdis-2015-208995.
    PubMed     Text format     Abstract available


  111. KLOP C, de Vries F, Bijlsma JW, Leufkens HG, et al
    Predicting the 10-year risk of hip and major osteoporotic fracture in rheumatoid arthritis and in the general population: an independent validation and update of UK FRAX without bone mineral density.
    Ann Rheum Dis. 2016 Mar 16. pii: annrheumdis-2015-208958.
    PubMed     Text format     Abstract available


  112. NIKIPHOROU E, Norton S, Young A, Carpenter L, et al
    Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds.
    Ann Rheum Dis. 2016 Mar 15. pii: annrheumdis-2015-208669.
    PubMed     Text format     Abstract available


  113. SINGH JA
    Cervical cancer risk with the use of tumour necrosis factor inhibitors in rheumatoid arthritis: to worry or not to worry?
    Ann Rheum Dis. 2016 Mar 7. pii: annrheumdis-2015-208526.
    PubMed     Text format    


  114. RIVIERE E, Ly B, Boudaoud S, Chavez H, et al
    Pitfalls for detecting interleukin-33 by ELISA in the serum of patients with primary Sjogren syndrome: comparison of different kits.
    Ann Rheum Dis. 2016;75:633-5.
    PubMed     Text format    


  115. SZCZERBA BM, Kaplonek P, Wolska N, Podsiadlowska A, et al
    Interaction between innate immunity and Ro52-induced antibody causes Sjogren's syndrome-like disorder in mice.
    Ann Rheum Dis. 2016;75:617-22.
    PubMed     Text format     Abstract available


    February 2016
  116. BAE SC, Kim J, Choe JY, Park W, et al
    A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study.
    Ann Rheum Dis. 2016 Feb 23. pii: annrheumdis-2015-207613.
    PubMed     Text format     Abstract available


  117. PETERFY C, Burmester GR, Bykerk VP, Combe BG, et al
    Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis.
    Ann Rheum Dis. 2016 Feb 10. pii: annrheumdis-2015-208258.
    PubMed     Text format     Abstract available


  118. KONIG MF, Giles JT, Nigrovic PA, Andrade F, et al
    Antibodies to native and citrullinated RA33 (hnRNP A2/B1) challenge citrullination as the inciting principle underlying loss of tolerance in rheumatoid arthritis.
    Ann Rheum Dis. 2016 Feb 10. pii: annrheumdis-2015-208529.
    PubMed     Text format     Abstract available


  119. VERSCHUEREN P, Westhovens R
    Separately tackling the development of erosions with denosumab: ultimately closing a gap in the treatment of patients with rheumatoid arthritis or trying too hard too late?
    Ann Rheum Dis. 2016 Feb 9. pii: annrheumdis-2015-208863.
    PubMed     Text format    


  120. MURPHY D, Mathew A, James B, Hutchinson D, et al
    Could the inhalation of cadmium and other metals in addition to textile dust inhalation account for the observed increased risk of rheumatoid arthritis in textile workers?
    Ann Rheum Dis. 2016 Feb 9. pii: annrheumdis-2016-209228.
    PubMed     Text format    


  121. MICHAUD K, Berglind N, Franzen S, Frisell T, et al
    Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease.
    Ann Rheum Dis. 2016 Feb 8. pii: annrheumdis-2015-208698.
    PubMed     Text format     Abstract available


  122. THORNTON CC, Al-Rashed F, Calay D, Birdsey GM, et al
    Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation.
    Ann Rheum Dis. 2016;75:439-48.
    PubMed     Text format     Abstract available


  123. SPREAFICO R, Rossetti M, van Loosdregt J, Wallace CA, et al
    A circulating reservoir of pathogenic-like CD4+ T cells shares a genetic and phenotypic signature with the inflamed synovial micro-environment.
    Ann Rheum Dis. 2016;75:459-65.
    PubMed     Text format     Abstract available


  124. SEROR R, Bootsma H, Saraux A, Bowman SJ, et al
    Defining disease activity states and clinically meaningful improvement in primary Sjogren's syndrome with EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).
    Ann Rheum Dis. 2016;75:382-9.
    PubMed     Text format     Abstract available


  125. BRITO-ZERON P, Kostov B, Solans R, Fraile G, et al
    Systemic activity and mortality in primary Sjogren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients.
    Ann Rheum Dis. 2016;75:348-55.
    PubMed     Text format     Abstract available


    January 2016
  126. MANFREDI AA, Baldini M, Camera M, Baldissera E, et al
    Anti-TNFalpha agents curb platelet activation in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2016 Jan 27. pii: annrheumdis-2015-208442.
    PubMed     Text format     Abstract available


  127. CONAGHAN PG, Ostergaard M, Bowes MA, Wu C, et al
    Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquanti
    Ann Rheum Dis. 2016 Jan 25. pii: annrheumdis-2015-208267.
    PubMed     Text format     Abstract available


  128. ZHANG J, Xie F, Yun H, Chen L, et al
    Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis.
    Ann Rheum Dis. 2016 Jan 20. pii: annrheumdis-2015-207870.
    PubMed     Text format     Abstract available


  129. KIEVIT W, van Herwaarden N, van den Hoogen FH, van Vollenhoven RF, et al
    Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study.
    Ann Rheum Dis. 2016 Jan 13. pii: annrheumdis-2015-208317.
    PubMed     Text format     Abstract available


  130. AJEGANOVA S, Humphreys JH, Verheul MK, van Steenbergen HW, et al
    Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts.
    Ann Rheum Dis. 2016 Jan 12. pii: annrheumdis-2015-208579.
    PubMed     Text format     Abstract available


  131. KANEKO Y, Atsumi T, Tanaka Y, Inoo M, et al
    Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study).
    Ann Rheum Dis. 2016 Jan 5. pii: annrheumdis-2015-208426.
    PubMed     Text format     Abstract available


  132. BURMESTER GR, Rubbert-Roth A, Cantagrel A, Hall S, et al
    Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).
    Ann Rheum Dis. 2016;75:68-74.
    PubMed     Text format     Abstract available


  133. STANFORD SM, Aleman Muench GR, Bartok B, Sacchetti C, et al
    TGFbeta responsive tyrosine phosphatase promotes rheumatoid synovial fibroblast invasiveness.
    Ann Rheum Dis. 2016;75:295-302.
    PubMed     Text format     Abstract available


  134. GUO C, Hu F, Yi H, Feng Z, et al
    Myeloid-derived suppressor cells have a proinflammatory role in the pathogenesis of autoimmune arthritis.
    Ann Rheum Dis. 2016;75:278-85.
    PubMed     Text format     Abstract available


  135. DURES E, Almeida C, Caesley J, Peterson A, et al
    Patient preferences for psychological support in inflammatory arthritis: a multicentre survey.
    Ann Rheum Dis. 2016;75:142-7.
    PubMed     Text format     Abstract available


  136. HOSOYA T, Iwai H, Yamaguchi Y, Kawahata K, et al
    Cell cycle regulation therapy combined with cytokine blockade enhances antiarthritic effects without increasing immune suppression.
    Ann Rheum Dis. 2016;75:253-9.
    PubMed     Text format     Abstract available


    December 2015
  137. HAUGEN IK, Hammer HB
    A need for new imaging modality to detect inflammation in rheumatoid arthritis and osteoarthritis?
    Ann Rheum Dis. 2015 Dec 23. pii: annrheumdis-2015-208661.
    PubMed     Text format    


  138. ROM AL, Wu CS, Olsen J, Jawaheer D, et al
    Parental rheumatoid arthritis and long-term child morbidity: a nationwide cohort study.
    Ann Rheum Dis. 2015 Dec 23. pii: annrheumdis-2015-208072.
    PubMed     Text format     Abstract available


  139. AJEGANOVA S, Svensson B, Huizinga TW, van der Helm-van Mil AH, et al
    Evaluation of the association between anticarbamylated protein antibodies and the longitudinal course of functional ability in rheumatoid arthritis.
    Ann Rheum Dis. 2015 Dec 23. pii: annrheumdis-2015-208954.
    PubMed     Text format    


  140. TOO CL, Muhamad NA, Ilar A, Padyukov L, et al
    Occupational exposure to textile dust increases the risk of rheumatoid arthritis: results from a Malaysian population-based case-control study.
    Ann Rheum Dis. 2015 Dec 17. pii: annrheumdis-2015-208278.
    PubMed     Text format     Abstract available


  141. TAKEUCHI T, Tanaka Y, Iwasaki M, Ishikura H, et al
    Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study.
    Ann Rheum Dis. 2015 Dec 15. pii: annrheumdis-2015-208279.
    PubMed     Text format     Abstract available


  142. SCHWENZER A, Jiang X, Mikuls TR, Payne JB, et al
    Identification of an immunodominant peptide from citrullinated tenascin-C as a major target for autoantibodies in rheumatoid arthritis.
    Ann Rheum Dis. 2015 Dec 9. pii: annrheumdis-2015-208495.
    PubMed     Text format     Abstract available


  143. HECHT C, Englbrecht M, Rech J, Schmidt S, et al
    Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA.
    Ann Rheum Dis. 2015;74:2151-6.
    PubMed     Text format     Abstract available


  144. TAYLOR PC, Genovese MC, Greenwood M, Ho M, et al
    OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy.
    Ann Rheum Dis. 2015;74:2123-9.
    PubMed     Text format     Abstract available


    November 2015
  145. ASKLING J, Berglind N, Franzen S, Frisell T, et al
    How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries.
    Ann Rheum Dis. 2015 Nov 30. pii: annrheumdis-2015-208105.
    PubMed     Text format     Abstract available


  146. GABAY C, McInnes IB, Kavanaugh A, Tuckwell K, et al
    Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2015 Nov 27. pii: annrheumdis-2015-207872.
    PubMed     Text format     Abstract available


  147. KRISHNAMURTHY A, Joshua V, Haj Hensvold A, Jin T, et al
    Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss.
    Ann Rheum Dis. 2015 Nov 26. pii: annrheumdis-2015-208093.
    PubMed     Text format     Abstract available


  148. D'AGOSTINO MA, Wakefield RJ, Berner-Hammer H, Vittecoq O, et al
    Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study.
    Ann Rheum Dis. 2015 Nov 20. pii: annrheumdis-2015-207709.
    PubMed     Text format     Abstract available


  149. TAKEUCHI T, Tanaka Y, Ishiguro N, Yamanaka H, et al
    Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, rando
    Ann Rheum Dis. 2015 Nov 19. pii: annrheumdis-2015-208052.
    PubMed     Text format     Abstract available


  150. RICHTER A, Listing J, Schneider M, Klopsch T, et al
    Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2015 Nov 13. pii: annrheumdis-2015-207838.
    PubMed     Text format     Abstract available


  151. KRABBE S, Ammitzboll-Danielsen M, Ostergaard M, Giard MC, et al
    Sensitivity and specificity of optical spectral transmission imaging in detecting joint inflammation in rheumatoid arthritis.
    Ann Rheum Dis. 2015 Nov 13. pii: annrheumdis-2015-208399.
    PubMed     Text format    


  152. VERMEIJ EA, Broeren MG, Bennink MB, Arntz OJ, et al
    Disease-regulated local IL-10 gene therapy diminishes synovitis and cartilage proteoglycan depletion in experimental arthritis.
    Ann Rheum Dis. 2015;74:2084-91.
    PubMed     Text format     Abstract available


  153. QIN B, Wang J, Yang Z, Yang M, et al
    Epidemiology of primary Sjogren's syndrome: a systematic review and meta-analysis.
    Ann Rheum Dis. 2015;74:1983-9.
    PubMed     Text format     Abstract available


  154. KIM SC, Schneeweiss S, Glynn RJ, Doherty M, et al
    Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.
    Ann Rheum Dis. 2015;74:1968-75.
    PubMed     Text format     Abstract available


  155. DU Y, Su Y, He J, Yang Y, et al
    Impact of the leucocyte immunoglobulin-like receptor A3 (LILRA3) on susceptibility and subphenotypes of systemic lupus erythematosus and Sjogren's syndrome.
    Ann Rheum Dis. 2015;74:2070-5.
    PubMed     Text format     Abstract available


    October 2015
  156. VAN DEN BOSCH WB, Mangnus L, van der Helm-van Mil AH
    Response to: 'The significance of the squeeze test to identify arthritis was underestimated or not?' by Luo et al.
    Ann Rheum Dis. 2015;74:e61.
    PubMed     Text format    


  157. LUO W, Zeng C, He H
    The significance of the squeeze test to identify arthritis was underestimated or not?
    Ann Rheum Dis. 2015;74:e60.
    PubMed     Text format    


  158. VAN DEN BOSCH WB, Mangnus L, Reijnierse M, Huizinga TW, et al
    The diagnostic accuracy of the squeeze test to identify arthritis: a cross-sectional cohort study.
    Ann Rheum Dis. 2015;74:1886-9.
    PubMed     Text format     Abstract available


  159. YAMADA T, Fedotovskaya O, Cheng AJ, Cornachione AS, et al
    Nitrosative modifications of the Ca2+ release complex and actin underlie arthritis-induced muscle weakness.
    Ann Rheum Dis. 2015;74:1907-14.
    PubMed     Text format     Abstract available


  160. CHEN Z, Kim SJ, Essani AB, Volin MV, et al
    Characterising the expression and function of CCL28 and its corresponding receptor, CCR10, in RA pathogenesis.
    Ann Rheum Dis. 2015;74:1898-906.
    PubMed     Text format     Abstract available


  161. SUURMOND J, Rivellese F, Dorjee AL, Bakker AM, et al
    Toll-like receptor triggering augments activation of human mast cells by anti-citrullinated protein antibodies.
    Ann Rheum Dis. 2015;74:1915-23.
    PubMed     Text format     Abstract available


    January 2015
  162. FLEISCHMANN R, Bananis E
    Response to: 'Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registry' by Favalli et al.
    Ann Rheum Dis. 2015;74:e6.
    PubMed     Text format    


  163. FAVALLI EG, Becciolini A, Biggioggero M, Marchesoni A, et al
    Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registry.
    Ann Rheum Dis. 2015;74:e5.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Rheumatoid Arthritis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: